

ORAMED PHARMACEUTICALS INC.  
Form NT 10-K  
November 29, 2007  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 12b-25**

SEC FILE NUMBER

**NOTIFICATION OF LATE FILING**

**000-50298**  
CUSIP NUMBER

**68403P 10 4**

(Check one):     Form 10-K    Form 20-F    Form 11-K    Form 10-Q    Form 10-D    Form N-SAR  
                   Form N-CSR  
                  For Period Ended: **August 31, 2007**  
                   Transition Report on Form 10-K  
  
                   Transition Report on Form 20-F  
  
                   Transition Report on Form 11-K  
  
                   Transition Report on Form 10-Q  
  
                   Transition Report on Form N-SAR  
  
                  For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I REGISTRANT INFORMATION**

**Oramed Pharmaceuticals Inc.**

Full Name of Registrant

**N/A**

Former Name if Applicable

**2 Elza Street**

Address of Principal Executive Office (*Street and Number*)

**Jerusalem, Israel 93706**

City, State and Zip Code

**PART II RULES 12b-25(b) AND (c)**

## Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form NT 10-K

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
  - (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject annual report or transition report on Form 10 Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
- X
-

**PART III NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

The Registrant is unable to file, without unreasonable effort and expense, its Form 10-KSB annual report for the period ended August 31, 2007 because its auditors have not yet had an opportunity to complete their review of the financial statements. It is anticipated that the Form 10-KSB annual report, along with the financial statements, will be filed on or before the 15th calendar day following the prescribed due date of the Registrant's Form 10-KSB.

**PART IV OTHER INFORMATION**

- (1) Name and telephone number of person to contact in regard to this notification  
**Nadav Kidron, 011.972.547.90.9058**  
(Name) (Area Code) (Telephone Number)
- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).  Yes  
 No
- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?  Yes  
 No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**ORAMED PHARMACEUTICALS INC.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 29, 2007

By: /s/ Nadav Kidron  
Nadav Kidron

President and Director

